Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
Azizi, Alexander A.
Hadjinicolaou, Andreas V.
Frontiers in Oncology
Frontiers Media S.A.
MetadataShow full item record
Azizi, A. A., Hadjinicolaou, A. V., Goncalves, C., Duckworth, A., & Basu, B. (2020). Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Frontiers in Oncology, 10 https://doi.org/10.3389/fonc.2020.570958
Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.
Oncology, Combined hepatocellular-cholangiocarcinoma, cHCC-ICC, cHCC-CCA, biphenotypic, primary liver cancer, genomics, systemic therapy
External DOI: https://doi.org/10.3389/fonc.2020.570958
This record's URL: https://www.repository.cam.ac.uk/handle/1810/311289
Attribution 4.0 International (CC BY 4.0)
Licence URL: https://creativecommons.org/licenses/by/4.0/